The Promise of Merck's Pembrolizumab in PD-L1-expressing NSCLC

Pembrolizumab was safe and effective in patients with locally advanced or metastatic non–small cell lung cancer that strongly expressed PD-L1, according to study results presented at the ASCO Annual Meeting.
Published Online: June 11, 2014

Edward B. Garon, MD, assistant clinical professor and director of the thoracic oncology program at the David Geffen School of Medicine at the University of California, Los Angeles, and colleagues sought to evaluate pembrolizumab (Merck) — previously known as lambrolizumab and MK-3475 — among patients with previously treated advanced NSCLC.

“We presented the initial data from lung cancer patients at the World Conference on Lung Cancer in Sydney last fall,” Garon told HemOnc Today. “The question at that time was whether the impressive efficacy and tolerable safety profile could be confirmed in a larger population. We have now demonstrated similar results in over 200 additional patients.”

The analysis included 217 patients who were tested for PD-L1 expression using immunohistochemistry (IHC).

Read the report here: http://bit.ly/1kn49ov

Source: Healio



Feature
Recommended Articles
The deal combines Humana's 3.2 million Medicare enrollees with Aetna's 1.26 million Medicare enrollees, giving the new combined company a strong position as the baby boomer population ages.
New delivery models related to the recent healthcare reform legislation may help drive up utilization, as discussed by Francois de Brantes, MS, MBA; Ateev Mehrotra, MD, MPH; and Arthur Vercillo, MD, FACS, in this seventh segment of the Healthcare Reform Stakeholders Summit, Spring 2015 series. They theorize that healthcare convenience and availability may actually lead to a loss in coordination of care.
With a growing understanding of the risk of cardiotoxicity associated with cancer treatment, cardio-oncology has emerged as an important subspecialty, resulting in the establishment of cardio-oncology programs most often based at or in collaboration with comprehensive cancer centers.
During this one-on-one interview, a part of the Oncology Stakeholders Summit, Spring 2015 series, Michael Kolodziej, MD, discusses payer considerations regarding coverage for new cancer treatments such as immuno-oncology therapies.
Metastatic colorectal cancer patients with higher body mass index (BMI) outlived patients with the lowest BMI by an average of 2-and-a-half months, according to new data presented at the European Society for Medical Oncology 17th World Congress on Gastrointestinal Cancer 2015.